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EPIDEMIOLOGY AND PREVENTION
Epidemiological Impact of Tenofovir Gel on the HIV
Epidemic in South Africa
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Background: Tenofovir gel, an antiretroviral-based vaginal micro-
bicide, reduced HIV acquisition by 39% in women in a recent
randomized controlled clinical trial in South Africa.
Methods: To inform policy, we used a dynamical model of HIV
transmission, calibrated to the epidemic in South Africa, to determine
the population-level impact of this microbicide on HIV incidence,
prevalence, and deaths and to evaluate its cost-effectiveness.
Results: If women use tenofovir gel in 80% or more of sexual
encounters (high coverage), it could avert 2.33 (0.12 to 4.63) million new
infections and save 1.30 (0.07 to 2.42) million lives and if used in 25% of
sexual encounters (low coverage), it could avert 0.50 (0.04 to 0.77)
million new infections and save 0.29 (0.02 to 0.44) million deaths, over
the next 20 years. At US $0.50 per application, the cost per infection
averted at low coverage is US $2392 (US $562 to US $4222) and the cost
per disability-adjusted life year saved is US $104 (US $27 to US $181); at
high coverage the costs are about 30% less.
Conclusions: Over 20 years, the use of tenofovir gel in South Africa
could avert up to 2 million new infections and 1 million AIDS deaths.
Even with low rates of gel use, it is highly cost-effective and compares
favorably with other control methods. This female-controlled prevention
method could have a significant impact on the epidemic of HIV in South
Africa. Programs should aim to achieve gel use in more than 25% of
sexual encounters to significantly alter the course of the epidemic.
Key Words: HIV prevention, microbicide gel, tenofovir, South
Africa, cost effectiveness
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INTRODUCTION
The global HIVepidemic continues unabated, and despite
recently observed declines in HIV incidence among young
women in some countries in Africa, incidence rates remain
unacceptably high.1 Efforts to reduce HIV transmission have yet
to show a significant population level effect in many countries
in Africa.2 The evidence that treating sexually transmitted
infections reduces HIV incidence remains equivocal;3 behavior
change interventions have not shown a demonstrable impact on
HIV incidence;4 male circumcision reduces the risk of infection
by about 60% in men and is now being made available in much
of Africa.5 A recent study reports that male circumcision might
reduce HIV infection directly in women, but the reduction was
not statistically significant in the trials quoted.6 Condoms are
effective, if used consistently and correctly, and promoting
condoms among sex workers has yielded positive results, but
condom use remains limited.7 Where it is available, antire-
troviral treatment has reduced mortality rates, but there is little
evidence that it has significantly reduced community-level
transmission because it is currently provided mainly in the late
stages of infection.8 There is therefore an urgent need for new
prevention technologies that women can use to reduce their risk
of infection.
In the Centre for the AIDS Program of Research in South
Africa (CAPRISA) 004 randomized controlled trial, a vaginal
microbicide containing 1% tenofovir significantly reduced the
transmission of HIV-19 from men to women. The availability of
this female-controlled method of prevention could have
a significant impact on the future epidemic of HIV. In countries
like South Africa, where the HIV epidemic is generalized and
incidence rates among young women are high,10,11 policies on
tenofovir gel are being developed for post-licensure imple-
mentation. To help inform policy development and resource
allocation, we estimate the potential long-term impact of
tenofovir gel on HIV prevalence, HIV incidence, and AIDS
mortality in South Africa and its cost-effectiveness.
METHODS
A mathematical model,12 previously developed to explore
the impact of male circumcision on the HIV epidemic, has been
adapted for this study. Briefly, we compartmentalize the
population into 5 groups: people who are not infected with
HIVand people in 4 stages of HIV infection. We assume a mean
survival time from HIV infection to death, without antiretroviral
treatment, of 11 years and let transmission rates fall as prevalence
rises to allow for heterogeneity in sexual risk behavior as
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discussed fully in our previous study.12 We fitted the model to
trends in the prevalence of HIVamong adults as estimated by the
Joint United Nations Program on HIV/AIDS.2 The model is not
structured by age or gender. Assuming that the microbicide
reduces male-to-female transmission with a relative risk of
infection r, say, but does not reduce female-to-male transmission,
then this is equivalent to a reduction in overall transmission with




.12 We have previously shown that the
long-term population level impact using this model, without
stratifying by gender, is not significantly different from the
impact calculated using a model that is stratified by gender.12
We consider 3 coverage scenarios, where coverage is
defined as the proportion of all sexual encounters that are
protected by the use of the gel. ‘‘High’’ is for women who used
the gel in 80% or more of sexual contacts in the CAPRISA 004
trial9 for which the relative risk of infection was rh = 0.46 (0.20
to 0.96; limits are 95% confidence intervals here and else-
where). We assume that the average coverage in the ‘‘high’’
scenario was 90%. If the relative risk of infection per sexual
encounter protected by the gel is r and the coverage is c then
the average risk, at coverage c, is:
rc ¼ rc þ ð1 cÞ ð1Þ
Setting c = 0.90 and rc = rh gives r = 0.40 (0.11 to 0.96).
For the ‘‘medium’’ scenario, we assume that coverage is 50%
so that rm = 0.70 (0.56 to 0.98) and for the low scenario that
coverage is 25% so that rl = 0.85 (0.78 to 0.99) (equation 1). In
short, based on the CAPRISA 004 trial results, we assume
90% (high) coverage achieves 60% protection from HIV, 50%
(medium) coverage achieves 30% protection, and 25% (low)
coverage achieves 15% protection.
We let the cost-effectiveness, C, be the cost of using the
microbicide divided by the reduction in the incidence of
infection. If the cost per dose is g, the coverage is c, and
susceptible women, who use the microbicide, have h sexual
contacts per year, then the annual cost is ghc. We let the
incidence of HIV infection among susceptible women be I, and
the reduction in the risk of infection resulting from the use of the





models, when the epidemic is far from elimination, the
proportional reduction in incidence is generally less than the
proportional reduction in transmission by an amount f, say,
which will depend on the natural history of the epidemic and the
structure of the model that is used to fit the data.13 The annual
incidence of HIV, per susceptible woman, is thenfrI, so that the




If averting one infection saves d years of disability-





Verguet et al14 suggested that the cost of the microbicide in
a developing country is US $0.50. In the CAPRISA 004 Trial,9
the cost of the gel was US $0.01, the tenofovir was donated free
for the trial but is likely to cost about US $0.02, whereas the cost
of the applicator was US $ 0.11 and of the wrapping US $ 0.16,
giving a total cost for 2 applications (1 before and 1 after the
sexual encounter) of g = US $0.60. Large-scale production of
the gel and cheaper applicators could reduce this cost further. For
the purposes of this analysis, the full trial production costs of the
product are used. Verguet et al14 estimate that averting 1 HIV
infection saves d = 23 DALYs. To decide if the use of the gel is
cost-effective, we compare the cost of preventing 1 person from
being infected with HIV with the life-time cost of keeping 1
person on ART, and we also compare the cost of saving 1 DALY
with the per capita gross national income per year.
RESULTS
The model provides a good fit to data from seropreva-
lence surveys in South Africa, and the predicted trends in HIV
prevalence, incidence, and mortality are shown in Figure 1. We
assume that the microbicide is rolled-out starting in 2012 and
is available throughout South Africa by 2015. HIV incidence
falls rapidly as gel use increases (Fig. 1, centre), and the
highest level of impact is seen by 2015. Prevalence falls less
rapidly as transmission declines (Fig. 1, left), and mortality
falls more slowly still (Fig. 1, right) because of the average life
expectancy of 11 years for people who are infected with HIV
and are not on ART; the full impact on mortality is not seen
until 2030.
Between 2011 and 2020, low coverage (25%) of the
microbicide would avert 0.25 (0.02 to 0.38) million incident
cases and prevent 0.05 (0.01 to 0.07) million deaths, whereas
high coverage (90%) would avert 1.10 (0.06 to 2.04) million
cases and prevent 0.20 (0.01 to 0.35) million deaths (Table 1).
In the following 10 years (2021–2030), the impact on
incidence would be only slightly greater, but the impact on
mortality would be much greater. Low coverage of the
microbicide would still avert 0.25 (0.02 to 0.39) million
incident cases but would prevent 0.24 (0.02 to 0.37) million
deaths, whereas high coverage would avert 1.23 (0.06 to 2.59)
million cases and prevent 1.10 (0.06 to 2.07) million deaths.
In the CAPRISA 004 trial,9 the annual incidence in the
placebo arm was I = 9.1% (6.9% to 11.7%). The women in
the trial had an average of 5 sexual encounters per month, with the
number decreasing from 8.5 to 3.0 per month at the end of
the trial, so that h  60 612 per year. Fitting our model to the
epidemic in South Africa, the reduction in incidence under
the high coverage scenario is 65% of the reduction in
transmission, whereas at low coverage, it is 53% of the reduction
in transmission so that f = 0.65 and 0.53 in the 2 scenarios.
Substituting these values in equation 2, the cost per infection
averted at 90% coverage is US $1701 (6US $1281), whereas at
25% coverage, it is US $2392 (6US$1830), and with equation 3,
the cost per DALYaverted at 90% coverage is US $74 (6US $56)
and at 25% coverage, is US $104 (6US $77) (Table 2).
DISCUSSION
Widespread use of the vaginal microbicide, tenofovir
gel, as part of prevention programs, could lead to significant
reductions in the rate of new HIV infections and AIDS-related
mortality. In South Africa, high coverage (tenofovir gel used in
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90% of sex encounters) could avert 2.33 (0.12 to 4.63) million
new infections and save 1.30 (0.07 to 2.42) million lives over
the next 20 years in South Africa. In a low-coverage scenario
(tenofovir gel used in 25% of sex encounters), it could avert
0.50 (0.04 to 0.77) million new infections and save 0.29 (0.02
to 0.44) million deaths over 20 years in South Africa.
At low coverage, the cost of preventing 1 person from
being infected with HIV is 28% of the life-time cost of
providing ART to 1 person which Verguet et al estimate to be
US $8396,14 whereas the cost of saving 1 DALY is only 2% of
the per capita gross national income per year,15 which in South
Africa is $5770.16 Condom social marketing, the use of sterile
needles, female condom use by sex workers, ART for the
prevention of mother-to-child transmission, blood safety,
sexually transmitted infection treatment, peer education, and
male circumcision were investigated by Verguet et al14 and
their cost-effectiveness lay between US $5/DALY for condom
social marketing in Chad and US $194/DALY for the use of
sterile needles in South Africa.17 The cost-effectiveness of
using tenofovir gel microbicides at about US $100 per DALY
saved (Table 2), compares favourably with these other
interventions. In this analysis, the cost of the microbicide is
US $0.60 per sexual encounter, but it is likely that this could be
significantly reduced especially if the cost of the applicator and
the wrapping can be reduced. Providing women with access to
this microbicide should be cost-saving and cost-effective.
None of the estimates allow for the savings in treatment and
hospitalization costs, which will be incurred by HIV-positive
people before they die or start ART and which will further
improve the cost-benefit ratio.
In countries where the incidence of HIV infection is
lower than it is in southern Africa, the cost-effectiveness will
be less favourable because the cost per infection averted rises
as the incidence falls (equation 1). In countries such as
Senegal, where the prevalence and the incidence are about
one-tenth of that in South Africa, tenofovir gel would be less
cost-effective if used in the general population. However, if gel
use can be targeted at women at highest risk, such as commercial
FIGURE 1. Trends in prevalence,
incidence, and mortality resulting
from the rollout of a vaginal micro-
bicide program between 2012 and
2015. The model is fitted to the
trend in HIV prevalence among
adults of age 15 years or more. Black
line (immediately above the shaded
areas): no intervention. Blue lines:
microbicide is used in 90% (high),
50% (medium), and 25% (low) of all
sex acts. Shaded areas give the 95%
confidence limits.




2011 to 2020 Prevalence 0.93 (0.05 to 1.72) 0.44 (0.03 to 0.72) 0.21 (0.01 to 0.32)
Incidence 1.10 (0.06 to 2.04) 0.53 (0.03 to 0.85) 0.25 (0.02 to 0.38)
Deaths 0.20 (0.01 to 0.35) 0.10 (0.01 to 0.16) 0.05 (0.01 to 0.07)
2021 to 2030 Prevalence 1.19 (0.06 to 2.42) 0.54 (0.03 to 0.90) 0.25 (0.02 to 0.38)
Incidence 1.23 (0.06 to 2.59) 0.56 (0.03 to 0.93) 0.25 (0.02 to 0.39)
Deaths 1.10 (0.06 to 2.07) 0.52 (0.03 to 0.85) 0.24 (0.02 to 0.37)
2011 to 2030 Prevalence 1.19 (0.06 to 2.42) 0.54 (0.03 to 0.90) 0.25 (0.02 to 0.38)
Incidence 2.33 (0.12 to 4.63) 1.09 (0.06 to 1.78) 0.50 (0.04 to 0.77)
Deaths 1.30 (0.07 to 2.42) 0.62 (0.04 to 1.01) 0.29 (0.02 to 0.44)
Data are given in columns assuming that the microbicide is used in 90%, 50%, and 25% of sex acts. Numbers are in millions and numbers in brackets give 95% confidence limits.
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sex workers, the impact of the gel on HIV-incidence would be
increased. Now that the effectiveness of tenofovir gel to
prevent HIV infection has been demonstrated, we hope that
further research into new drugs and new delivery methods will
lead to lower costs with even greater efficacy.
The CAPRISA 004 trial included information, counsel-
ling, condom promotion, and treatment of sexually transmitted
infections for all study participants. Hence, the trial’s
effectiveness level estimates, which we have used in this
analysis, provide an incremental measure of adding tenofovir
gel to an existing prevention program. This highlights the need
for tenofovir gel to be implemented as part of a combination
prevention approach.
The model we used is not stratified on age and sex but
captures the most important features of the impact of vaginal
microbicides on the transmission of HIV. A model structured on
age and sex would provide further insights into the way in which
microbicide use can best be targeted at those women at highest
risk. For example, the incidence of HIV in women in South
Africa peaks at the age of about 25 years, and close to 60% of all
new infections in women are among those aged between 20 and
30 years18 so that targeting women in this age group, at least
initially, could yield substantial benefits.
The model did not include tenofovir resistance because
the CAPRISA 004 trial showed no evidence of tenofovir
resistance in women who became infected with HIV in the
CAPRISA 004 trial. Resistance may, however, become an
important consideration over time as tenofovir use for AIDS
treatment becomes widespread. Further, the model did not
include any impact of tenofovir gel on female-to-male
transmission, as there is currently no evidence for this.
Although the factor f, which relates the reduction in
population level incidence to the reduction in the individual
risk of infection, depends on the details of the epidemic and
the structure of the model, it is unlikely to differ greatly for
countries in East and southern Africa where the epidemic
pattern is similar to that in South Africa. If epidemics can be
brought close to elimination, formally with R0 close to 1, a
small reduction in individual risk can lead to a much greater
proportional reduction in population level incidence so that the
cost-effectiveness would be correspondingly greater.
The concept of combination prevention draws upon the
idea that multiple prevention interventions can achieve
synergy and thereby reduce HIV incidence to a greater extent
than possible with each singly. The synergy goal of
combination prevention is critical for the eventual reversal
in the current upward trend in the HIV epidemic. Because
young women have the highest HIV incidence rates in the
southern African epidemic, high coverage of tenofovir gel in
this group in combination with high coverage of circumcision
in men plus education, HIV testing, and condom promotion
could achieve the synergy necessary to turn the tide of the
epidemic in this region.
The most important limitation of this analysis lies in the
uncertainty in the estimates of the extent to which gel use
reduces transmission and further studies to confirm the results
of the CAPRISA 004 trial, which should also provide better
estimates of the impact, are urgently needed.
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TABLE 2. The Cost Effectiveness of the Use of a Vaginal










25% 2392 (1830) 8396 104 (77) 5770
90% 1701 (1281) 74 (56)
Numbers in brackets are 95% confidence limits. The cost per infection not averted is
the estimated cost of keeping a person on ART for 23 years.14
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